FPR2 is a therapeutic target in lung cancer [ 2018 - 2021 ]

Research Grant

Researchers: A/Pr Steven Bozinovski (Principal investigator) ,  A/Pr Daniel Steinfort ,  A/Pr Louis Irving ,  Prof Brendan Jenkins ,  Prof Ross Vlahos

Brief description Lung cancer remains the biggest cause of cancer related deaths and chronic smoking is the major risk factor. We have recently demonstrated that a protein termed SAA contributes to damaging inflammation in chronic smokers that develop emphysema through activation of a receptor called FPR2. We will determine whether naturally derived products termed pro-resolving mediators that target this same FPR2 receptor will prove to be a novel and effective treatment for lung cancer.

Funding Amount $AUD 910,550.21

Funding Scheme Project Grants

Notes Standard Project Grant